Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Procoralan Making a Strong Entry to the new ESC Guidelines for the Management of Heart Failure


News provided by

Servier

06 Jun, 2012, 23:01 GMT

Share this article

Share toX

Share this article

Share toX

PARIS, June 7, 2012 /PRNewswire/ --

The new ESC guidelines for the diagnosis and management of heart failure include the heart ratelowering drug, Procoralan® (ivabradine)

Less than 2 years after the publication in The Lancet of the SHIFT study results demonstrating its benefits in heart failure, Procoralan® is now integrated in the new ESC guidelines for the management of heart failure.[1]

The guidelines, presented this week at the ESC's Heart Failure Congress in Belgrade, Serbia, have been updated for the first time since 2008. They make recommendations for treatment based upon evidence for established and new diagnostic tests, and therapies for heart failure.

"The revised ESC Heart Failure guidelines aim to help physicians in everyday clinical medical decision-making and if implemented offer a real opportunity to improve the outcome of patients with this condition," commented John McMurray, Professor of Medical Cardiology at the University of Glasgow and principal author of the new ESC guidelines. Heart failure patients with elevated heart rates are at a significantly greater risk of death or hospitalisation, which both impacts patients' quality of life and ultimate outcome and puts pressure on healthcare systems.[2]  

In addition, a new indication for ivabradine in chronic heart failure was granted by the European Medicines Agency in February 2012. This was based on new data from the SHIFT study[3]   in which patients with an elevated heart rate of greater than or equal to 75 beats per minute (bpm) showed a significant reduction in the primary composite endpoint (CV death and hospitalisation for worsening heart failure) of 24% (p<0.0001), reduction in risk of cardiovascular death by 17% (p=0.0166), all-cause death by 17% (p=0.0109) and heart failure hospitalisation by 30% (p<0.0001).

The new indication and the new ESC guidelines for the management of heart failure are the two major advances which will allow heart failure patients to benefit from ivabradine.

About chronic heart failure

Chronic heart failure affects 15 million patients in Europe (2% to 3% of the overall population).[4]  It is a disabling condition and, despite improvements in treatment and management, generally has a poor prognosis. Heart failure impairs the heart's ability to pump effectively and to maintain sufficient circulation to meet the body's needs. It is most commonly caused by acute (myocardial infarction) or chronic (angina pectoris) ischaemia (coronary artery disease).[5, 6]

About ivabradine

Procoralan® (ivabradine) is the only drug to reduce heart rate selectively by inhibiting one of the electrical signals that determine heart rate-the pacemaker If current.[3] Procoralan reduces heart rate without significantly impacting the ability of the heart muscle to pump blood.[3,9]

Procoralan was launched in January 2006 for the treatment of stable angina. It is indicated in the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal (sinus) rhythm unable to tolerate or with a contraindication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is >60 bpm.[3]

Procoralan was subsequently approved by the European Commission for the treatment of patients with chronic heart failure in February 2012.  It is indicated in the treatment of chronic heart failure in patients with normal (sinus) rhythm and whose heart rate is 75 bpm or above, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.[8]   The decision to authorise the indication for Procoralan in heart failure followed the review of data from the SHIfT trial, the largest ever morbidity-mortality study of treatments for chronic heart failure involving more than 6000 patients. It demonstrated that the treatment significantly reduced the risk of death and hospitalisation for heart failure, and improved the quality of life of people living with the disease.[10,11] This reduction in mortality was highly significant in patients with a heart rate of 75 bpm or above, for whom Procoralan is now indicated.[3]

Depending on the country, ivabradine is available as Procoralan(R), Coralan(R), Coraxan(R), or Corlentor(R)

 

NOTES TO EDITORS

About the SHIfT study

SHIfT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) is a randomised, double-blind, placebo-controlled study involving 6505 people in 37 countries. This study set out to evaluate whether the addition of the If inhibitor, Procoralan, to optimal guidelines-based treatment improves cardiovascular outcomes in patients with moderate to severe chronic heart failure, reduced left ventricular ejection fraction and heart rate of 70 bpm or above.[10]

SHIfT showed that the If inhibitor Procoralan reduced the risk of the primary composite endpoint (CV death and hospitalisation for worsening heart failure) by 18% (p<0.0001), death from heart failure by 26% (p=0.014), and the risk of hospitalisation by 26% (p<0.0001). The benefits were seen even though the study patients were already taking currently recommended heart failure treatments.[9] In the subgroup of patients with heart rate above 75 bpm at baseline (n = 4150), Procoralan reduced the risk of the primary composite endpoint (CV death and hospitalisation for worsening heart failure) by 24 % (p<0.0001), cardiovascular death by 17% (p=0.0166), and all-cause death by 17% (p=0.0109).

A pre-specified sub-study of 1944 patients from the main study population showed that the reduction in heart rate achieved through treatment with Procoralan was associated with almost double the improvement in quality of life compared with the control group. This improvement was observed in both the disease-related component and the social component of the scores.[11]

Quality of life assessments were conducted using the Kansas City Cardiomyopathy Questionnaire, a 23-item, self-administered questionnaire which quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.[11]

In an echocardiography sub-study, Procoralan was shown to lead to a reduction in the heart's left ventricular end-systolic volume (the blood volume remaining in the left ventricle after contraction), which resulted in improved efficiency of the left ventricle and of overall heart function.[12]

About the BEAUTIFUL study

BEAUTIFUL (morBidity-mortality EvAlUaTion of the Ifinhibitor ivabradine in patients with coronary heart disease and left ventricULar dysfunction) was a randomised, double-blind, placebo-controlled study involving 10 917 people in 33 countries. The study set out to evaluate whether mortality and morbidity would be reduced by the addition of the selective heart ratelowering treatment, ivabradine, to current therapy in patients with stable CAD and LV systolic dysfunction.[13] On entering the trial 87% of patients were receiving beta-blockers, 89% renin-angiotensin system agents, 94% antithrombotic agents, 76% lipid-lowering agents, and 12% calcium channel blockers. 37% of patients also had diabetes and 40% had metabolic syndrome.[14]

The main efficacy criterion was the composite of cardiovascular death, hospitalisation for acute MI or hospitalisation for new-onset or worsening heart failure. While the study showed no difference in the rate of the primary composite outcome in the ivabradine group by comparison with the placebo group, an over one third (36%) reduction in risk of hospitalisation for fatal or non-fatal heart attack was shown in a broad range of patients with stable coronary artery disease (CAD) and left ventricular dysfunction with heart rate ≥70 bpm. The drug also reduced by 30% (ARR = 1%) the risk of patients having to undergo revascularisation procedures.[13] In a subgroup of patients with limiting angina (n=1507), the benefit of ivabradine was even more pronounced, with a 24% reduction in the primary endpoint and a 42% reduction in the risk of hospitalisation for fatal or non-fatal heart attack (ARR = 2.7%, p=0.021)).[15] In those with an elevated heart rate (>70 bpm) the risk was reduced by 73% (ARR = 4.6%, p=0.002).[15]

About Servier

Servier is France's leading independent pharmaceutical company and the country's second largest drug company. Servier is present in 140 countries. R&D at Servier spans a range of therapeutic fields, with the main areas of focus being cardiovascular disease, neuroscience, cancer, metabolic disorders, and rheumatology. In the field of cardiovascular disease in particular, Servier is one of the principal research organisations dedicated to the development of new medicines. Servier has a long-standing interest in the field of cardiovascular disease, as attested by the fact that 63% of Servier's global turnover from medicines is made up of drugs targeting cardiovascular diseases.

References

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. DOI:10.1093/eurheart/ehs104
  2. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-371
  3. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. DOI 10.1007/s00392-012-0467-8
  4. European Society of Cardiology (ESC). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2388-2442.NICE guidelines for the management of chronic heart failure in adults in primary and secondary care. Available at http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf (Last accessed May 22, 2012)
  5. Juenger J, Schellberg D, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002; 87:235-241.
  6. Fox K et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372: 817-821
  7. Procoralan Summary of Product Characteristics. http://www.emc.medicines.org.uk (Last accessed May 22, 2012)
  8. Andrews TC, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88: 92-100
  9. DiFrancesco D and Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004; 64(16): 1757-1765.
  10. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376:875-85
  11. Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32:2395-2404.
  12. Tardif JC, O'Meara E, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011, DOI: 10.1093/eurheartj/ehr311. Available at http://eurheartj.oxfordjournals.org/
  13. Fox K, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372, :807-816.
  14. Fox K, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Am Heart J. 2006; 152: 860-866
  15. Fox K et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized controlled BEAUTIFUL trial. Eur Heart J. 2009; 30: 2337-2345

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.